Specifying the Anti-inflammatory Effects of Ziltivekimab

NCT06263244 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Atherosclerosis
Inflammation

Interventions

DRUG: Ziltivekimab
DRUG: Placebo

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)